Stock Analysis of Nuvectis Pharma Inc (NVCT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code NVCT
Close 6.77
Change -0.060 / 0.878 %
Volume 51266.00
Vol Change 10407.00 / 25.47 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Nuvectis Pharma Inc
PE (TTM)

-5.09

Very Poor
Price / Book

7.54

Very Poor
Price / Sales

-27.78

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

124270 K

Enterprise Value

105144 K

ROA (TTM)

-109.38

Very Poor
ROE (TTM)

-148.20

Very Poor
Net Margin (TTM)

545.77

Excellent
Revenue

100.00 %

0
Net Profit

17.02 %

-22334.00 K
Debt to Equity

0

Excellent
Altman Z Score

3.64

Good
Quick Ratio

0

Poor
Cash Ratio

2.74

Good


Highs/Lows of Nuvectis Pharma Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week6.34 6.78 % 1.58 % 7.03856.011813-Jun-2410-Jun-24
Two Week6.77 0 % 2.92 % 7.03855.9513-Jun-2405-Jun-24
One Month6.77 0 % 3.52 % 7.3685.8523-May-2420-May-24
Three Month9.15 26.01 % 5.46 % 11.895.8518-Mar-2420-May-24
Six Months8.54 20.73 % 15.09 % 12.15.8514-Mar-2420-May-24
One year18.21 62.82 % 24.22 % 18.45995.8515-Jun-2320-May-24
Two year10.22 33.76 % 45.41 % 18.655.8514-Jun-2320-May-24


Technical View of Nuvectis Pharma Inc
RSI

52.47

Neutral
MACD

-0.0278

Bullish
ADX

9.35

Neutral
Super Trend

5.47

Mild Bullish
Williams %R

-24.67

Strong Bearish
CCI

86.91

Strong Bearish


EMA 5

6.69

Bullish
EMA 15

6.58

Strong Bullish
EMA 50

6.90

Mild Bearish
EMA 100

7.54

Mild Bearish
SMA 100

7.58

Mild Bearish
SMA 200

8.78

Mild Bearish
SMA 5 / 20

6.68 / 6.47

Bullish
SMA 15 / 50

6.52 / 6.72

Mild Bearish
SMA 50 / 200

6.72 / 8.78

Strong Bearish




Charts of Nuvectis Pharma Inc


Returns of Nuvectis Pharma Inc with Peers
Period / StockNVCTHBIOKNTEDBTX
1 Week6.78%-1.53%-0.376%-3.73%
1 Mth0%-15.60%2.32%-3.91%
3 Mth-26.01%-32.52%4.74%22.75%
6mth-20.73%-41.16%97.76%81.85%
1 Year-62.82%-49.48%-61.26%25.58%
2 Year-33.76%-21.12%-76.82%-39.01%
5 Years-39.18%--
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Nuvectis Pharma Inc with Peers
Ratio / StockNVCTHBIOKNTEDBTX
PE-5.09-14.19-1.11-1.94
P/B7.541.630.6111.48
ROA-109.38-6.25-50.28-50.31
ROE-148.20-11.52-56.86-76.48
Debt To Equity00.5200.00560.0438
Revenue0
100.00 % 		112524 K
0.716 % 		0
% 		0
%
Net Income-22334.00 K
17.02 % 		-3263.00 K
65.71 % 		-127154.00 K
9.36 % 		-63005.00 K
21.58 %


Technicals of Nuvectis Pharma Inc with Peers
Technical / StockNVCTHBIOKNTEDBTX-
ADX9.3530.0934.5333.82
CMF-0.200-0.347-0.168-0.402
MFI48.6828.9429.0441.59
RSI52.4733.4762.6151.68
MACD Abv SignalTrueTrueFalseFalse
Price Above 50 MATrueFalseTrueTrue-
Price Above 200 MAFalseFalseTrueTrue-


About : Nuvectis Pharma Inc

Address : 1 Bridge Plaza, Fort Lee, NJ, United States, 07024
Tel : 201 614 3150
URL : https://www.nuvectis.com
Code : NVCT, ISIN : US67080T1088, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 04_Feb_2022
Employee Count : 13

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.


Note : All Data Generated at the End of Trading Hours (EOD Data)